Jaguar Health, Inc.
Index- P/E- EPS (ttm)-1.29 Insider Own0.30% Shs Outstand44.71M Perf Week-3.69%
Market Cap23.21M Forward P/E- EPS next Y-0.67 Insider Trans7.59% Shs Float- Perf Month-13.16%
Income-58.60M PEG- EPS next Q-0.23 Inst Own9.00% Short Float- Perf Quarter-56.50%
Sales5.70M P/S4.07 EPS this Y60.80% Inst Trans17.24% Short Ratio1.84 Perf Half Y-70.65%
Book/sh0.18 P/B1.71 EPS next Y21.90% ROA-99.70% Target Price10.88 Perf Year-93.66%
Cash/sh0.23 P/C1.33 EPS next 5Y40.00% ROE-321.00% 52W Range0.27 - 5.16 Perf YTD-70.37%
Dividend- P/FCF- EPS past 5Y- ROI-104.20% 52W High-94.03% Beta1.81
Dividend %- Quick Ratio1.20 Sales past 5Y98.30% Gross Margin61.50% 52W Low14.15% ATR0.03
Employees52 Current Ratio1.50 Sales Q/Q116.70% Oper. Margin- RSI (14)42.36 Volatility9.00% 8.88%
OptionableYes Debt/Eq3.96 EPS Q/Q-40.00% Profit Margin- Rel Volume0.33 Prev Close0.29
ShortableYes LT Debt/Eq3.10 Earnings- Payout- Avg Volume2.44M Price0.31
Recom1.50 SMA20-2.67% SMA50-18.91% SMA200-69.31% Volume817,792 Change4.83%
Jul-07-21Initiated Cantor Fitzgerald Overweight $5
Jul-11-17Initiated Rodman & Renshaw Buy $2
Jul-01-22 04:15PM  
Jun-29-22 08:30AM  
Jun-22-22 08:30AM  
Jun-21-22 08:30AM  
Jun-13-22 08:30AM  
Jun-10-22 04:15PM  
Jun-09-22 08:30AM  
May-25-22 08:30AM  
May-24-22 08:30AM  
May-23-22 07:00AM  
May-19-22 08:30AM  
May-17-22 08:55AM  
May-11-22 02:30PM  
May-10-22 08:00AM  
May-06-22 04:15PM  
May-05-22 02:15PM  
May-03-22 08:30AM  
Apr-27-22 10:20AM  
Apr-20-22 08:30AM  
Apr-15-22 04:15PM  
Apr-06-22 08:30AM  
Apr-05-22 08:30AM  
Mar-31-22 06:30AM  
Mar-14-22 01:15PM  
Mar-11-22 05:00PM  
Mar-07-22 08:30AM  
Mar-01-22 08:30AM  
Feb-16-22 08:30AM  
Feb-15-22 08:30AM  
Feb-10-22 08:30AM  
Feb-01-22 08:30AM  
Jan-24-22 08:30AM  
Jan-13-22 08:30AM  
Jan-12-22 08:58AM  
Jan-04-22 08:30AM  
Dec-22-21 08:30AM  
Dec-21-21 03:38PM  
Dec-20-21 08:30AM  
Dec-13-21 08:30AM  
Dec-10-21 08:00AM  
Dec-06-21 08:30AM  
Nov-19-21 02:21PM  
Nov-17-21 08:00AM  
Nov-16-21 08:30AM  
Nov-15-21 07:00AM  
Nov-10-21 08:30AM  
Nov-08-21 08:30AM  
Nov-02-21 08:30AM  
Nov-01-21 08:30AM  
Oct-29-21 04:15PM  
Oct-28-21 04:50AM  
Oct-27-21 12:00PM  
Oct-25-21 08:30AM  
Oct-07-21 09:45AM  
Sep-30-21 08:30AM  
Sep-27-21 08:30AM  
Sep-23-21 08:30AM  
Sep-16-21 08:30AM  
Sep-15-21 08:30AM  
Sep-14-21 08:30AM  
Sep-09-21 08:30AM  
Sep-07-21 02:32PM  
Sep-03-21 04:15PM  
Aug-23-21 08:30AM  
Aug-19-21 08:30AM  
Aug-17-21 08:30AM  
Aug-13-21 09:00PM  
Aug-10-21 04:30PM  
Aug-06-21 04:15PM  
Jul-28-21 08:30AM  
Jul-26-21 08:30AM  
Jul-23-21 04:15PM  
Jul-19-21 08:30AM  
Jul-14-21 08:30AM  
Jul-09-21 04:15PM  
Jun-23-21 08:30AM  
Jun-22-21 07:17PM  
Jun-11-21 04:15PM  
Jun-04-21 04:15PM  
Jun-02-21 08:30AM  
Jun-01-21 08:30AM  
May-26-21 08:30AM  
May-20-21 08:30AM  
May-19-21 11:00AM  
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lizak Carol R.Chief Financial OfficerSep 13Buy2.517,96820,0007,968Mar 30 09:32 PM
CONTE LISA ACEO and PresidentSep 13Buy2.517,96820,0008,003Mar 30 09:26 PM